Your browser is no longer supported. Please, upgrade your browser.
Processa Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.91 Insider Own6.10% Shs Outstand13.37M Perf Week-15.00%
Market Cap113.81M Forward P/E- EPS next Y-0.53 Insider Trans-33.64% Shs Float6.17M Perf Month-31.74%
Income-19.00M PEG- EPS next Q-0.10 Inst Own12.20% Short Float1.03% Perf Quarter19.80%
Sales- P/S- EPS this Y-263.00% Inst Trans0.05% Short Ratio0.70 Perf Half Y70.41%
Book/sh1.72 P/B4.15 EPS next Y-26.20% ROA-138.90% Target Price- Perf Year-47.96%
Cash/sh0.97 P/C7.39 EPS next 5Y- ROE-180.10% 52W Range3.40 - 14.24 Perf YTD8.26%
Dividend- P/FCF- EPS past 5Y-5.70% ROI- 52W High-49.86% Beta0.11
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low110.00% ATR0.61
Employees14 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)25.37 Volatility9.62% 7.88%
OptionableNo Debt/Eq0.00 EPS Q/Q-361.70% Profit Margin- Rel Volume1.19 Prev Close7.72
ShortableYes LT Debt/Eq0.00 EarningsMar 25 AMC Payout- Avg Volume90.49K Price7.14
Recom2.00 SMA20-19.19% SMA50-31.95% SMA200-9.33% Volume107,483 Change-7.51%
Mar-25-21 04:06PM  
Mar-22-21 09:15AM  
Mar-17-21 09:15AM  
Mar-02-21 09:15AM  
Feb-22-21 08:30AM  
Feb-19-21 05:16AM  
Feb-17-21 08:00AM  
Jan-11-21 10:50AM  
Nov-16-20 12:48PM  
Nov-12-20 05:02PM  
Nov-05-20 09:15AM  
Nov-03-20 09:20AM  
Oct-13-20 09:30AM  
Oct-07-20 09:25AM  
Oct-06-20 04:05PM  
Oct-02-20 06:00AM  
Aug-27-20 09:30AM  
Aug-20-20 09:30AM  
Jun-01-20 09:30AM  
Mar-30-20 04:00PM  
Mar-17-20 09:30AM  
Mar-05-20 09:30AM  
Feb-25-20 09:30AM  
Feb-13-20 09:30AM  
Dec-20-19 04:10PM  
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yorke Justin WDirectorApr 14Sale9.429,70091,374248,272Apr 15 04:33 PM
Yorke Justin WDirectorApr 13Sale9.866,50064,090257,972Apr 15 04:33 PM
BESSER JAMES EApr 08Sale10.76400,0004,304,000648,300Apr 08 06:05 PM
BESSER JAMES EApr 07Sale10.6716,000170,7201,048,300Apr 08 06:05 PM
BESSER JAMES EApr 06Sale10.9131,771346,6221,064,300Apr 08 06:05 PM
BESSER JAMES E10% OwnerFeb 22Sale11.5620,929241,9391,096,071Feb 22 08:13 PM
BESSER JAMES E10% OwnerFeb 19Sale11.203,00033,6001,117,000Feb 22 08:13 PM
BESSER JAMES E10% OwnerFeb 18Sale11.355,00056,7501,120,000Feb 22 08:13 PM
BESSER JAMES E10% OwnerOct 02Buy4.0430,000121,200405,000Oct 13 06:33 PM